| Gentium Partners Joins as GP, with JNPMEDI Serving as Technical Advisor
| Korean MedTech Startups Seeking FDA Approval and Global Market Expansion Draw Attention
AI-powered clinical trial consulting firm JNPMEDI (CEO KwunHo Jeong) has been selected, together with Gentium Partners (CEO HyunJoon Park), for the 2025 KSMBA Rookie League Fund under the Ministry of SMEs and Startups’ first regular investment initiative. Gentium Partners will serve as General Partner (GP), while JNPMEDI will act as Technical Advisor, launching full-scale strategic investment and support for MedTech startups undergoing or preparing for FDA approval.
Korea Venture Investment Corp. and private Limited Partners (LPs) are expected to commit a total of KRW 20 billion to the fund. Gentium Partners will manage the fund, while JNPMEDI, as a regulatory expert, will conduct in-depth assessments of FDA viability, technical capabilities, and market entry strategies to help guide investment decisions.
Amid challenges such as complex regulatory processes and a limited domestic market, the fund focuses on identifying early-stage MedTech startups with globally competitive technologies and capabilities. It supports their value growth through end-to-end assistance—from strategic investment to regulatory consulting and FDA submission planning.
“Regulatory approval is one of the biggest challenges for Korean MedTech startups seeking to enter global markets," said KwunHo Jeong, CEO of JNPMEDI. “Through this fund, we aim to provide practical support to companies with strong technologies and market potential, helping them cross global thresholds more quickly and with greater confidence.”
“This fund goes beyond simply providing capital—it aims to offer integrated post-investment support that spans technical advisory, regulatory readiness, and market entry strategy, covering the entire commercialization process,” added HyunJoon Park, CEO of Gentium Partners. “Through close collaboration with JNPMEDI, we will identify globally competitive MedTech startups and help create successful FDA approval cases.”
Through this Rookie League selection, Gentium Partners and JNPMEDI are expected to establish a strong collaborative framework and solidify their position as key partners in advancing Korea’s medical device industry into global markets.
| Gentium Partners Joins as GP, with JNPMEDI Serving as Technical Advisor
| Korean MedTech Startups Seeking FDA Approval and Global Market Expansion Draw Attention
AI-powered clinical trial consulting firm JNPMEDI (CEO KwunHo Jeong) has been selected, together with Gentium Partners (CEO HyunJoon Park), for the 2025 KSMBA Rookie League Fund under the Ministry of SMEs and Startups’ first regular investment initiative. Gentium Partners will serve as General Partner (GP), while JNPMEDI will act as Technical Advisor, launching full-scale strategic investment and support for MedTech startups undergoing or preparing for FDA approval.
Korea Venture Investment Corp. and private Limited Partners (LPs) are expected to commit a total of KRW 20 billion to the fund. Gentium Partners will manage the fund, while JNPMEDI, as a regulatory expert, will conduct in-depth assessments of FDA viability, technical capabilities, and market entry strategies to help guide investment decisions.
Amid challenges such as complex regulatory processes and a limited domestic market, the fund focuses on identifying early-stage MedTech startups with globally competitive technologies and capabilities. It supports their value growth through end-to-end assistance—from strategic investment to regulatory consulting and FDA submission planning.
“Regulatory approval is one of the biggest challenges for Korean MedTech startups seeking to enter global markets," said KwunHo Jeong, CEO of JNPMEDI. “Through this fund, we aim to provide practical support to companies with strong technologies and market potential, helping them cross global thresholds more quickly and with greater confidence.”
“This fund goes beyond simply providing capital—it aims to offer integrated post-investment support that spans technical advisory, regulatory readiness, and market entry strategy, covering the entire commercialization process,” added HyunJoon Park, CEO of Gentium Partners. “Through close collaboration with JNPMEDI, we will identify globally competitive MedTech startups and help create successful FDA approval cases.”
Through this Rookie League selection, Gentium Partners and JNPMEDI are expected to establish a strong collaborative framework and solidify their position as key partners in advancing Korea’s medical device industry into global markets.